Proton-pump inhibitors have been reported to influence the human immune system, we therefore evaluated the effect of lansoprazole, a proton-pump inhibitor, on humoral immunity. Patients with gastric ulcer received lansoprazole 30 mg/day for 8 weeks, and serum immunoglobulins were evaluated before and upon completion of the treatment. There were 79 patients with gastric ulcer; 51 were H. pylori-infected and 28 were H. pylori-uninfected. Eighteen patients positive for H. pylori were receiving at least one non-steroidal anti-inflammatory drug, and 12 patients negative for H. pylori received one non-steroidal anti-inflammatory drug. H. pylori-infected patients showed significant increases in serum immunoglobulins G and M 8 weeks after the start of lansoprazole treatment (P<O.OOI for IgG and P<O.OI for IgM), but uninfected patients did not. Even when H. pylori-infected patients receiving a nonsteroidal anti-inflammatory drug or low-dose aspirin were analyzed separately, these increases were seen (P<O.OOI for IgG and P<0.005 for IgM). Lansoprazole elevated serum levels of immunoglobulins G and M in gastric ulcer patients with H. pylori infection, particularly in those receiving non-steroidal anti-inflammatory drugs. Deducing from these observations, lansoprazole might alter the Thl shift in the immune response induced by H. pylori infection.
Histamine type 2 receptor antagonists (H2RA) and proton-pump inhibitors (PPIs) are two major medical options for treating peptic ulcers, and both types of medication have been reported to influence the human immune system (1-4). PPIs can influence the immune system not only through their pharmaceutical action but also through their anti-Helicobacter pylori (anti-H. pylori) effects (5) (6) (7) (8) (9) . In addition, lansoprazole (LPZ), a PPI, has recently been reported to increase the peripheral platelet count in patients with idiopathic thrombocytopenic purpura, irrespective of H. pylori eradication, suggesting that the drug can alter the H. pyloriinduced shift toward a Th 1 immune response (10) . Non-steroidal anti-inflammatory drugs (NSAIDs) are well-known inducers of peptic ulcers and are reported to influence the immune system (11-16). To address the possible immunotropic action of LPZ, we evaluated the humoral immunity of patients with gastric ulcers by assessing changes in serum immunoglobulin levels after treatment with LPZ.
MATERIALS AND METHODS

Patients
After obtaining informed consent to evaluate H. pylori status and immunohematologic variables, we examined 208 dyspeptic patients endoscopically for the presence of gastric ulcer. Gastric ulcer was diagnosed according to the classification system of Sakita and Miwa (17) , and patients with gastric ulcer of stage A I to H2 (presence of ulcer crater) were enrolled in the study. Because PPIs are accepted to be first-line drugs in treating and preventing NSAlDs-induced ulcer, we were unable to select H2RAs as the first-line drugs in the current study resulting in the lack of a control group using H2RAs.
Methods
Infection by H. pylori was determined by anti-H. pylori IgG antibody, rapid urease test (RUT) and pathologic findings. Biopsy specimens were obtained from the antrum and lower body in the greater curvature and from major lesions. Samples from the antrum and lower body were placed into RUT kits, and the result was evaluated 24 hours later. Serum anti-H. pylori IgG antibody was measured with a commercially available ELISA kit. The definition ofH. pylori infection required two or more of the following findings to be positive: RUT, pathology and anti-H. pylori IgG antibody. According to the direction of LPZ use in Japan, the patients were given LPZ at 30 mg/day for 8 weeks. These patients were evaluated with special reference to serum immunoglobulin levels (lgG, IgA and IgM): before the treatment, upon completion of treatment and 12 to 16 weeks after the completion. In addition, hematologic variables such as the complete blood count and leukocyte differentials were also checked. Serum levels of IgG, IgA and IgM were measured by an automated turbidimetric immunoprecipitation method. Medications of such patients were unchanged except for the addition of LPZ, even if the patients were receiving NSAlDs, because LPZ can heal peptic ulcer under such conditions (17) .
Patients with malignant disease, hematologic disease, rheumatic disease and infectious disease were excluded from the study. In addition, patients receiving corticosteroids, immunosuppressive agents or antibiotics were also excluded.
Statistical analysis
Differences were analyzed by means of Student's paired and unpaired t-tests. P values less than 0.05 were accepted as statistically significant.
RESULTS
A total of 79 patients with gastric ulcer were enrolled in the study. Most of H. pylori-infected patients received this treatment before the eradication therapy was officially permitted. Patients' characteristics are shown in Table I . Fifty-one patients were positive for H. pylori, and 18 patients were receiving at least one NSAID: low-dose aspirin (81 mg/day) for preventing cardiovascular diseases (N= I0), and various NSAIDs for pain control (N=9). One patient was receiving both low-dose aspirin and celecoxib. Twenty-eight of the 79 patients were negative for H. pylori, and 12 of these 28 were receiving an NSAID (low-dose aspirin, N=9). On the second endoscopic examination (8 weeks after starting the treatment), ulcer healing was confirmed in all patients: stage S I or S2 (absence of ulcer craters) (17) . Changes in serum levels of IgG, IgA and IgM levels are shown in Table II . As a whole, H. pylori-positive patients showed increases in serum IgG and IgM 8 weeks after the initiation of LPZ treatment (P<O.OOI and 0.01, respectively). When such patients were classified as NSAID users (N=18) and NSAID non-users (N=33), NSAID users showed increases in both IgG and IgM (P=O.OOI and 0.002, respectively), whereas non-NSAID users failed to show significant increases (P=0.083 and 0.167). Even when the 10 patients with gastric ulcer who were receiving low-dose aspirin were analyzed separately, these increases were seen (P=0.022 and 0.018). In contrast, no changes in serum immunoglobulins were observed in H. pylori-negative patients (Table III) . Concerning pre-treatment levels of serum immunoglobulins, H. pylori-infected patients with gastric ulcer showed suppressed levels of serum immunoglobulins compared to those of uninfected patients (P<0,05 for IgG and P<0.02 for IgM: Table IV) .
Hematologic variables including the complete blood count and leukocyte differentials were not influenced by the LPZ treatment (data not shown).
DISCUSSION
We examined the influence of LPZ on systemic humoral immunity in gastric ulcer patients without immunohematologic disorder by analyzing changes in serum immunoglobulin levels after treatment with LPZ. After 8 weeks of LPZ treatment, we observed elevated serum levels of both IgG and IgM in H. pylori-infected patients but not in H. pylori- P=0.0009*, 0.0007**, 0.0219*** (12) (13) (14) (15) (16) , although the precise mechanisms underlying these changes remain to be clarified. Indomethacine, an established NSAID, has been reported to influence both Th I and Th2 cells, and the degree of regulation may differ between these two types of lymphocytes. Some researchers report that Th I is more likely to be influenced (13) (14) (15) (16) ; others disagree. We thus assumed LPZ, due to termination of the immunotropic effect of NSAIDs, could alter the Th I shift to up-regulate immunoglobulin synthesis in H. pylori-infected patients with gastric ulcer. The precise mechanism of this immunotropic action is unclear, but it appears to depend on living H. pylori in the gastric mucosa.
Pre-8W
Lower serum levels of immunoglobulins were observed in gastric ulcer patients infect with H. pylori than those uninfected with it. Although the number of evaluated patients is too small to draw any conclusions, H. pylori infection might suppress immunoglobulin synthesis, possibly due to the Th I shift in the lymphocyte response. Further investigation on this issue is required to clarify the role of H. pylori infection.
